GEMPHARMATECH released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, a year-on-year increase of 11.9%
According to the Zhitong Finance APP, GEMPHARMATECH disclosed its third-quarter report for 2025. The company achieved revenue of 576 million yuan in the first three quarters, a year-on-year increase of 12.92%; the net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 11.9%; the net profit excluding non-recurring gains and losses was 92.79 million yuan, a year-on-year increase of 29.21%; the basic earnings per share were 0.27 yuan
According to the Zhitong Finance APP, GEMPHARMATECH (688046.SH) disclosed its third-quarter report for 2025. The company achieved revenue of 576 million yuan in the first three quarters, a year-on-year increase of 12.92%; the net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 11.9%; the net profit excluding non-recurring gains and losses was 92.79 million yuan, a year-on-year increase of 29.21%; basic earnings per share were 0.27 yuan
